Inquiry Basket
Loading ......
Vitamin B12 has emerged as a highly effective biological shuttle in modern drug delivery systems, not because of its nutritional role alone, but due to its highly evolved, receptor-mediated transport pathway in humans. In biopharmaceutical research, this natural trafficking mechanism is increasingly being repurposed to carry proteins, peptides, nucleic acids, and imaging agents across biological barriers that typically limit therapeutic efficiency.
Understanding how Vitamin B12 conjugates interact with their receptors is essential for designing next-generation targeted delivery systems with higher uptake efficiency, improved tissue specificity, and reduced systemic loss.
Vitamin B12 possesses a unique corrinoid architecture centered around a cobalt ion embedded within a macrocyclic "corrin ring." This structure forms a rigid yet modifiable scaffold that enables conjugation without completely disrupting receptor recognition.
However, despite its biological compatibility, Vitamin B12 cannot passively diffuse across membranes due to its relatively large molecular weight (~1355 Da). Instead, it relies entirely on an orchestrated cascade of carrier proteins and receptors to move through the body.
The structural modularity of B12—particularly its variable upper axial ligand—provides an opportunity for chemical modification while preserving its transport functionality. This makes it an attractive candidate for conjugation strategies in drug delivery design.
Vitamin B12 transport is one of the most complex nutrient trafficking systems in human physiology, involving sequential binding and receptor exchange across multiple anatomical compartments:
This sequential handoff mechanism creates multiple checkpoints for specificity, which can be exploited to enhance drug targeting precision.
At the molecular level, Vitamin B12 conjugates interact with a series of high-affinity receptors and transport proteins that govern uptake efficiency and cellular specificity.
TC-II is the primary plasma transporter of Vitamin B12. Its structure contains an α6–α6 barrel domain that securely binds B12 in a "base-on" conformation. The receptor-binding region is exposed on an extended surface, enabling interaction with CD320 on target cells.
This complex is particularly important in cancer biology, where CD320 overexpression significantly enhances uptake of B12-bound ligands, creating a natural targeting route for tumor-selective drug delivery.
The Cubam system, composed of Cubilin and Amnionless, is responsible for intestinal absorption of the B12–intrinsic factor complex. This receptor-mediated endocytosis process is highly selective and ensures efficient uptake even at low luminal concentrations, making it a key gateway for oral drug delivery strategies.
CD320 is widely expressed across hepatocytes, fibroblasts, and various malignant cell types. Its elevated expression in tumors makes it a strategic target for Vitamin B12-conjugated therapeutics, particularly in oncology applications where receptor density directly influences intracellular drug accumulation.
Vitamin B12 conjugation has significantly improved oral bioavailability of large biologics such as G-CSF and erythropoietin (EPO). In epithelial models (e.g., Caco-2 monolayers), B12-conjugated proteins show markedly enhanced absorption compared to unmodified counterparts, which typically fail to survive gastrointestinal transport.
Similarly, insulin-loaded B12-based nanoparticles demonstrate increased intestinal permeability and sustained glucose-lowering effects, highlighting the potential of receptor-mediated oral peptide delivery.
In oncology, Vitamin B12 serves as a precision targeting ligand. For example, B12-modified sericin–PBLG micelles loaded with paclitaxel selectively accumulate in CD320-overexpressing gastric cancer cells. Once internalized, these systems disrupt mitochondrial membrane potential and activate caspase-dependent apoptosis pathways, effectively overcoming drug resistance.
Additionally, B12-linked photodynamic agents and small-molecule conjugates can induce stress responses such as ER stress and unfolded protein response (UPR), triggering alternative cell death pathways like paraptosis.
Vitamin B12 has also been used to transport peptide nucleic acids (PNA) and other nucleic acid analogs. In bacterial systems, B12 conjugates exploit BtuB receptor pathways to cross outer membranes, while molecular dynamics simulations help optimize binding efficiency and intracellular release.
Beyond therapeutics, B12 conjugates are increasingly used in imaging applications. Fluorescent B12–metal complexes enable real-time tracking of receptor-mediated uptake, while radiolabeled cobalamin derivatives provide quantitative biodistribution data in vivo. These tools are essential for validating ligand–receptor interactions during drug development.
The success of B12-based delivery systems is strongly dependent on the chemistry used to attach therapeutic payloads. Common linker types include:
Among these, cleavable linkers—particularly disulfide-based systems—are increasingly favored due to their ability to release cargo in the reductive intracellular environment.
Position-specific conjugation also plays a crucial role. The 5′ hydroxyl group of Vitamin B12 is commonly used due to its accessibility and minimal interference with receptor binding, though alternative positions can significantly alter uptake efficiency.
Understanding how B12 conjugates behave in biological systems requires a combination of structural and dynamic analytical tools:
Together, these techniques allow researchers to correlate structural design with functional transport efficiency.
Despite significant progress, several barriers remain in optimizing Vitamin B12-based delivery systems:
At the same time, structural insights into TC-II, intrinsic factor, and Cubam receptors continue to accelerate rational design strategies. Advances in cleavable chemistry and tumor-targeting applications are expanding the scope of B12 beyond nutrient transport into a multifunctional delivery platform.
Vitamin B12 conjugates represent a rare convergence of biological compatibility and engineering potential. By leveraging its naturally evolved receptor-mediated transport system, researchers are transforming a simple micronutrient into a versatile delivery vehicle for drugs, genes, and diagnostic agents.
The ability to track and manipulate ligand–receptor interactions at molecular resolution is reshaping how targeted therapies are designed. As conjugation chemistry and structural biology continue to mature, Vitamin B12-based systems are expected to play an increasingly central role in precision biopharmaceutical transport strategies.
Vitamin B12 naturally follows a highly efficient receptor-mediated transport pathway involving intrinsic factor (IF), Cubam receptors, and CD320 receptors. This multi-step uptake system allows B12-conjugated drugs to "hitchhike" through biological barriers that typically block large biomolecules, making it an attractive carrier for proteins, peptides, and nucleic acids.
B12 conjugates bind to Transcobalamin II (TC-II) in the bloodstream and are recognized by CD320 receptors on the cell surface. This interaction triggers receptor-mediated endocytosis, allowing the conjugate to be internalized and transported into intracellular compartments where the therapeutic payload can be released.
Vitamin B12 has been successfully used to deliver a wide range of therapeutics, including:
Its versatility comes from its ability to bind different linkers and maintain receptor recognition.
Linkers connect the Vitamin B12 molecule to therapeutic cargos and determine how and when the drug is released. Common linkers include ester, amide, carbamate, and disulfide bonds. Among these, disulfide linkers are often preferred because they are cleavable inside cells under reductive conditions, enabling controlled intracellular drug release.
Despite their advantages, several challenges remain:
References
| Target | Cat. No. | Product Name | Host | Application | |
| Vitamin B12 | HMABPY073 | RHA™ anti-Vitamine B12 monoclonal antibody, clone VB12 | Mouse | ELISA, LFIA | Inquiry |
| DPATB-H83238 | Anti-Vitamin B12 polyclonal antibody | Rabbit | ELISA | Inquiry | |
| Folate | DMAB3387 | Anti-Folate monoclonal antibody, clone A9/34 | Mouse | RIA, EIA | Inquiry |
| DMAB3388 | Anti-Folate monoclonal antibody, clone C763F | Mouse | cELISA | Inquiry | |
| DMAB3390 | Anti-Folate monoclonal antibody, clone C765F | Mouse | cELISA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| Vitamin B12 | DAG3037 | Vitamin B12 [BSA] | BSA | N/A | Inquiry |
| DAG3038 | Vitamin B12 [HRP] | HRP | N/A | Inquiry | |
| DAG3039 | Vitamin B12 [KLH] | KLH | N/A | Inquiry | |
| DISNJ01 | Vitamin B12 Standard Solution | N/A | ELISA | Inquiry | |
| DAGA-068B | Vitamine B12 [BSA] | BSA | LFIA | Inquiry | |
| DAGA-073K | Vitamine B12 [KLH] | KLH | Immunogen | Inquiry | |
| DAGT5413-HRP | Vitamine B12 [HRP] | HRP | ELISA | Inquiry | |
| DAG271S | Vitamin B12 [HSA] | HSA | ELISA | Inquiry | |
| DAG545S | Vitamin B12 [HSA-Biotin] | HSA-Biotin | ELISA | Inquiry | |
| DAG-WT2686 | Vitamin B12 control | Unconjugated | Immunoassays | Inquiry | |
| VB12 | DAGA-068O | Vitamin B12 [OVA] | OVA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| Vitamin B12 | DEIA280 | Vitamin B12 ELISA Kit | 96T | N/A | Quantitative | food | Inquiry |
| DEIA2541 | Food Vitamin B12 ELISA Kit | 96T | Quantitative | multivitamin tablets, capsules, multivitamin juices, multivitamin jam, grain products, multivitamin sweets | Inquiry | ||
| DEIASL091 | Vitamin B12 ELISA Kit | 96T | Quantitative | cereals, milk, milk powder | Inquiry | ||
| DEIACL6 | CDSimple™ Vitamin B12 Chemiluminescent ELISA Kit | 96T, 192T | Quantitative | Serum | Inquiry | ||
| VB12 | DEIA2451 | Vitamin B12 ELISA Kit | 96T | N/A | Quantitative | food | Inquiry |
| DEIA-JY2109 | Vitamin B12 (Cobalamin) ELISA Kit | 96T | N/A | Quantitative | Food and dietary supplements. | Inquiry | |
| DEIA280NS | Vitamin B12 (Cobalamin) Plate Kit | 96T | N/A | Quantitative | Food | Inquiry | |
| Folic acid | DEIAH4170 | Human 5-MTHF(5-Methyltetrahydrofolate) ELISA Kit | 96T | Human | Quantitative | Serum, plasma, tissue homogenates and other biological fluids | Inquiry |
| Folate | DEIACL2 | CDSimple™ Folate & Vitamin B12 Chemiluminescent ELISA Kit | 96T, 192T | Quantitative | Serum, Plasma | Inquiry | |
| DEIACL4 | CDSimple™ Folate Chemiluminescent ELISA Kit | 96T, 192T | Quantitative | Serum | Inquiry |
Loading ......
